U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07171723) titled 'Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment' on Sept. 08.
Brief Summary: This clinical study investigates how blocking a hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are already being treated with semaglutide (a GLP-1 receptor agonist). The study uses LEAP2, a naturally occurring hormone that can inhibit the ghrelin receptor, which is involved in stimulating hunger.
The purpose of the study is to better understand how the ghrelin system functions when appetite is already suppressed by semaglutide treatment. Participants wi...